AirSculpt Reports Improved Performance in 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy AIRS?
Source: Newsfilter
- Performance Recovery: In Q4 2025, AirSculpt reported a case volume of 2,604, a 15% decline from Q4 2024, yet adjusted EBITDA improved to $2.5 million from $1.9 million year-over-year, indicating a gradual recovery in profitability amidst challenges.
- Revenue Decline: For the full year 2025, revenue totaled $151.8 million, down 15.8% from $180.4 million in 2024, reflecting pressures from intensified market competition and changing consumer demand impacting overall performance.
- Enhanced Financial Flexibility: As of December 31, 2025, the company had $8.4 million in cash and $5.0 million in borrowing capacity, and raised $14.8 million in Q1 2026 while paying down $11.0 million in debt, reducing total debt to approximately $45.0 million, thereby strengthening its financial foundation for future growth.
- Outlook: The company projects 2026 revenue between $151 million and $157 million, with adjusted EBITDA guidance of $15 million to $17 million, reflecting management's cautious optimism about future performance, particularly as same-store sales show signs of recovery.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AIRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AIRS
About AIRS
AirSculpt Technologies, Inc., through its wholly owned subsidiaries, is a provider of practice management services to professional associations (PAs) located throughout the United States, Canada, and the United Kingdom. The Company owns and operates non-clinical assets and provides its management services to the PAs through management services agreements (MSAs). It operates through the direct medical procedure services segment. The Company offers fat removal procedures across treatment areas. It also offers fat transfer procedures that use the patient’s own fat cells to enhance the breasts, buttocks, hips, or other areas and do not require silicone or foreign materials to be implanted. Its body contouring procedures include the Power BBL, a Brazilian butt lift procedure, the Up a Cup, a breast enhancement procedure, and the Hip Flip, an hourglass contouring procedure. Its AirSculpt + procedure permanently removes fat and tightens the skin with unparalleled precision and finesse.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AirSculpt Reports Improved Performance in 2025 Financial Results
- Performance Recovery: In Q4 2025, AirSculpt reported a case volume of 2,604, a 15% decline from Q4 2024, yet adjusted EBITDA improved to $2.5 million from $1.9 million year-over-year, indicating a gradual recovery in profitability amidst challenges.
- Revenue Decline: For the full year 2025, revenue totaled $151.8 million, down 15.8% from $180.4 million in 2024, reflecting pressures from intensified market competition and changing consumer demand impacting overall performance.
- Enhanced Financial Flexibility: As of December 31, 2025, the company had $8.4 million in cash and $5.0 million in borrowing capacity, and raised $14.8 million in Q1 2026 while paying down $11.0 million in debt, reducing total debt to approximately $45.0 million, thereby strengthening its financial foundation for future growth.
- Outlook: The company projects 2026 revenue between $151 million and $157 million, with adjusted EBITDA guidance of $15 million to $17 million, reflecting management's cautious optimism about future performance, particularly as same-store sales show signs of recovery.
See More
AirSculpt to Report Q4 and FY 2025 Results on April 2, 2026
- Earnings Report Schedule: AirSculpt Technologies will announce its fourth quarter and fiscal year 2025 financial results before market open on April 2, 2026, which is expected to provide investors with critical financial data and future outlook.
- Conference Call Details: Following the earnings release, AirSculpt will host a conference call at 8:30 a.m. Eastern Time, where investors can dial 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using conference ID 13758597 to participate.
- Webcast Access: Investors can access the earnings release webcast via the investor relations section of AirSculpt's website, with a replay available for approximately 90 days, ensuring that investors can stay informed at their convenience.
- Company Overview: AirSculpt is a next-generation body contouring treatment designed for comfort and precision, utilizing minimally invasive procedures to remove fat and tighten skin, allowing for quick healing and precise results, thereby enhancing the company's competitive edge in the premium body sculpting market.
See More
NASDAQ 100 Pre-Market Indicator Rises Significantly
- Market Indicator Surge: The NASDAQ 100 Pre-Market Indicator rises by 266.97 points to 24,647.7, indicating a positive shift in market sentiment that may attract more investors to tech stocks.
- Active Stock Performance: CytomX Therapeutics, Inc. (CTMX) increases by $2.34 to $7.02 with a trading volume of 27,793,236 shares, reflecting optimistic short-term prospects for the company.
- ETF Trading Dynamics: ProShares UltraPro QQQ (TQQQ) climbs $1.46 to $47.39 with 6,584,506 shares traded, representing a 170.8% increase from its 52-week low, showcasing strong investor interest in tech stocks.
- Earnings Forecast Revisions: Circle Internet Group, Inc. (CRCL) rises $5.795 to $121.18, with an expected EPS of $0.22 for the fiscal quarter ending September 2026, indicating market confidence in its future profitability.
See More
Zeta Global Surpasses Quarterly Earnings Expectations
- Earnings Beat: Zeta Global Holdings reported earnings of $0.28 per share, exceeding the Zacks Consensus Estimate of $0.23, reflecting a 40% increase from last year's $0.20, indicating a significant improvement in profitability.
- Significant Revenue Growth: The company posted revenues of $394.64 million for the quarter, surpassing the Zacks Consensus Estimate of $380 million and marking a 25.4% increase from $314.67 million a year ago, demonstrating strong market demand.
- Underperformance in Market: Despite exceeding earnings expectations, Zeta's stock has declined approximately 26.4% since the beginning of the year, compared to a 0.1% drop in the S&P 500, reflecting investor concerns about the company's future performance.
- Cautious Outlook: With a current Zacks Rank of 3 (Hold), investors are cautious about earnings expectations for the upcoming quarters, especially given the Technology Services industry's ranking in the bottom 38%.
See More
Friday's Underperforming Sectors: Construction, Healthcare, and Medical Professionals
Market Performance: Hospital and medical practitioners' shares are down approximately 1.7% on Friday, with Agilon Health and AirSculpt Technologies leading the decline at 9% and 8.3%, respectively.
Sector Laggards: The construction sector, along with hospital and medical practitioners, is identified as a laggard in the market on Friday.
Video Coverage: A video segment highlights the performance of these sectors, focusing on the laggards in the market.
Author's Perspective: The opinions expressed in the article are those of the author and do not necessarily represent the views of Nasdaq, Inc.
See More
Three Health Care Stocks That Could Revitalize Your Portfolio This November
Oversold Stocks in Health Care: The health care sector has several oversold stocks, presenting potential buying opportunities for undervalued companies, particularly those with a Relative Strength Index (RSI) below 30.
Inotiv Inc Performance: Inotiv Inc reported strong contract awards and anticipates fourth-quarter revenue between $137.5 million and $138.5 million, despite its stock falling 38% recently, with an RSI of 26.7.
Airsculpt Technologies Update: Airsculpt Technologies faced disappointing third-quarter results and lowered its FY25 revenue outlook, leading to a 60% stock drop over the past month, with an RSI of 29.3.
Neuronetics Sales Guidance: Neuronetics cut its FY2025 sales guidance, resulting in a 40% decline in stock value over the past month, and it currently has an RSI of 23.9.
See More
AirSculpt Reports Improved Performance in 2025 Financial Results
- Performance Recovery: In Q4 2025, AirSculpt reported a case volume of 2,604, a 15% decline from Q4 2024, yet adjusted EBITDA improved to $2.5 million from $1.9 million year-over-year, indicating a gradual recovery in profitability amidst challenges.
- Revenue Decline: For the full year 2025, revenue totaled $151.8 million, down 15.8% from $180.4 million in 2024, reflecting pressures from intensified market competition and changing consumer demand impacting overall performance.
- Enhanced Financial Flexibility: As of December 31, 2025, the company had $8.4 million in cash and $5.0 million in borrowing capacity, and raised $14.8 million in Q1 2026 while paying down $11.0 million in debt, reducing total debt to approximately $45.0 million, thereby strengthening its financial foundation for future growth.
- Outlook: The company projects 2026 revenue between $151 million and $157 million, with adjusted EBITDA guidance of $15 million to $17 million, reflecting management's cautious optimism about future performance, particularly as same-store sales show signs of recovery.
See More
AirSculpt to Report Q4 and FY 2025 Results on April 2, 2026
- Earnings Report Schedule: AirSculpt Technologies will announce its fourth quarter and fiscal year 2025 financial results before market open on April 2, 2026, which is expected to provide investors with critical financial data and future outlook.
- Conference Call Details: Following the earnings release, AirSculpt will host a conference call at 8:30 a.m. Eastern Time, where investors can dial 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using conference ID 13758597 to participate.
- Webcast Access: Investors can access the earnings release webcast via the investor relations section of AirSculpt's website, with a replay available for approximately 90 days, ensuring that investors can stay informed at their convenience.
- Company Overview: AirSculpt is a next-generation body contouring treatment designed for comfort and precision, utilizing minimally invasive procedures to remove fat and tighten skin, allowing for quick healing and precise results, thereby enhancing the company's competitive edge in the premium body sculpting market.
See More
NASDAQ 100 Pre-Market Indicator Rises Significantly
- Market Indicator Surge: The NASDAQ 100 Pre-Market Indicator rises by 266.97 points to 24,647.7, indicating a positive shift in market sentiment that may attract more investors to tech stocks.
- Active Stock Performance: CytomX Therapeutics, Inc. (CTMX) increases by $2.34 to $7.02 with a trading volume of 27,793,236 shares, reflecting optimistic short-term prospects for the company.
- ETF Trading Dynamics: ProShares UltraPro QQQ (TQQQ) climbs $1.46 to $47.39 with 6,584,506 shares traded, representing a 170.8% increase from its 52-week low, showcasing strong investor interest in tech stocks.
- Earnings Forecast Revisions: Circle Internet Group, Inc. (CRCL) rises $5.795 to $121.18, with an expected EPS of $0.22 for the fiscal quarter ending September 2026, indicating market confidence in its future profitability.
See More
Zeta Global Surpasses Quarterly Earnings Expectations
- Earnings Beat: Zeta Global Holdings reported earnings of $0.28 per share, exceeding the Zacks Consensus Estimate of $0.23, reflecting a 40% increase from last year's $0.20, indicating a significant improvement in profitability.
- Significant Revenue Growth: The company posted revenues of $394.64 million for the quarter, surpassing the Zacks Consensus Estimate of $380 million and marking a 25.4% increase from $314.67 million a year ago, demonstrating strong market demand.
- Underperformance in Market: Despite exceeding earnings expectations, Zeta's stock has declined approximately 26.4% since the beginning of the year, compared to a 0.1% drop in the S&P 500, reflecting investor concerns about the company's future performance.
- Cautious Outlook: With a current Zacks Rank of 3 (Hold), investors are cautious about earnings expectations for the upcoming quarters, especially given the Technology Services industry's ranking in the bottom 38%.
See More
Friday's Underperforming Sectors: Construction, Healthcare, and Medical Professionals
Market Performance: Hospital and medical practitioners' shares are down approximately 1.7% on Friday, with Agilon Health and AirSculpt Technologies leading the decline at 9% and 8.3%, respectively.
Sector Laggards: The construction sector, along with hospital and medical practitioners, is identified as a laggard in the market on Friday.
Video Coverage: A video segment highlights the performance of these sectors, focusing on the laggards in the market.
Author's Perspective: The opinions expressed in the article are those of the author and do not necessarily represent the views of Nasdaq, Inc.
See More
Three Health Care Stocks That Could Revitalize Your Portfolio This November
Oversold Stocks in Health Care: The health care sector has several oversold stocks, presenting potential buying opportunities for undervalued companies, particularly those with a Relative Strength Index (RSI) below 30.
Inotiv Inc Performance: Inotiv Inc reported strong contract awards and anticipates fourth-quarter revenue between $137.5 million and $138.5 million, despite its stock falling 38% recently, with an RSI of 26.7.
Airsculpt Technologies Update: Airsculpt Technologies faced disappointing third-quarter results and lowered its FY25 revenue outlook, leading to a 60% stock drop over the past month, with an RSI of 29.3.
Neuronetics Sales Guidance: Neuronetics cut its FY2025 sales guidance, resulting in a 40% decline in stock value over the past month, and it currently has an RSI of 23.9.
See More
